ReviewOphthalmology and therapy2026
Global Perspectives on Therapy for Noninfectious Conjunctival Hyperemia: A Narrative Review.
Review in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Smartphone-Based Automated Quantification of Bulbar Conjunctival Hyperemia Using Vessel Density Mapping.Translational vision science & technology · 2026Article
- Conjunctival Vascular Metrics Using Automated Vessel Detection from Slit Lamp Images for Hyperemia Severity Assessment.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conjunctival hyperemia is one of the most frequent ophthalmologic presentations and may adversely affect quality of life due to associated discomfort and aesthetic concerns. In many countries, the prevalence of noninfectious conjunctival hyperemia is increasing due to lifestyle factors and the shift to technology-based employment. Management of noninfectious conjunctival hyperemia is typically aimed at addressing the underlying cause while alleviating signs and symptoms. However, an underlying cause might not be identified, treatment may not immediately reduce redness, or residual redness might persist. Topical treatment options include lubricants, decongestants, antihistamines/mast cell stabilizers, and anti-inflammatory drugs. Among these, ocular decongestants provide effective short-term relief, but the use of α1- (phenylephrine, tetrahydrozoline) or mixed α1/α2- (naphazoline, oxymetazoline) adrenergic receptor agonists is associated with tachyphylaxis and rebound redness. A highly selective α2- adrenergic receptor agonist (brimonidine 0.025%) reduces ocular redness without evidence of tachyphylaxis over 29 days and with minimal rebound redness upon discontinuation; however, longer-term effectiveness has not been evaluated. Other unmet needs pertain to the management of noninfectious conjunctival hyperemia as an aesthetic issue and the need to educate patients about the risks of surgical eye-whitening procedures and national recalls. Region- or country-specific unmet needs include a lack of awareness of the need for clinical assessment and appropriate treatment of ocular redness. While many cases of noninfectious conjunctival hyperemia can be self-treated, unmet needs remain with respect to access to care and patient awareness/knowledge of safe and appropriate treatment options and the importance of clinical consultation. The development of management guidelines specific to noninfectious conjunctival hyperemia is warranted to address patients' clinical and aesthetic concerns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.